Delving into the Latest Updates on The Children's Hospital of Zhejiang University School of Medicine with Synapse

Overview

Tags

Hemic and Lymphatic Diseases

Urogenital Diseases

AAV based gene therapy

CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

CAR-T	1
AAV based gene therapy	1

Top 5 Target	Count

factor IX(Coagulation factor IX)	1
BCMA x CD70	1

Ureteral stents are crucial adjunctive devices following urolithiasis surgery, serving to support the ureter and facilitate urine drainage. However, the application of these stents can lead to complications such as urinary tract infections, lumbar pain, and bladder irritative symptoms, which significantly impact the quality of life in pediatric patients. Novel designs, such as anti-reflux stents equipped with valves, have been optimized to enhance unidirectional urine flow while effectively preventing retrograde urine flow. It is anticipated that these designs could alleviate symptoms of lumbar pain and urinary tract infections, thereby improving the postoperative recovery quality in children. Current adult studies suggest that anti-reflux stents might reduce urine reflux but may also be associated with significantly stronger urinary symptoms. To date, there have been no pediatric studies reported on the efficacy of anti-reflux stents. The aim of this study is to investigate the effectiveness and related complications of anti-reflux stents used in pediatric urolithiasis surgery at the Children's Hospital affiliated with Zhejiang University School of Medicine, by comparing them with conventional stents.

Start Date10 Oct 2024

Sponsor / Collaborator

The Children's Hospital of Zhejiang University School of Medicine

100 Clinical Results associated with The Children's Hospital of Zhejiang University School of Medicine

Login to view more data

0 Patents (Medical) associated with The Children's Hospital of Zhejiang University School of Medicine

Login to view more data

782

Literatures (Medical) associated with The Children's Hospital of Zhejiang University School of Medicine

31 Dec 2024·Hematology

A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens

Review

Author: Shen, Yao-Jia ; Zhu, Hong-Hu ; Xiong, Zhen-Yu ; Zhang, Shi-Zhong

Philadelphia chromosome-positive acute lymphoblastic leukemia (PH + ALL) is the most common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis. Previously, the only curative treatment option in PH + ALL was allogeneic hematopoietic stem cell transplantation (Allo-HSCT). Since 2000, targeted therapy combined with chemotherapy, represented by the tyrosine kinase inhibitor Imatinib, has become the first-line treatment for PH + ALL. Currently, the remission rate and survival rate of Imatinib are superior to those of simple chemotherapy, and it can also improve the efficacy of transplantation. More recently, some innovative immune-targeted therapy greatly improved the prognosis of PH + ALL, such as Blinatumomab and Inotuzumab Ozogamicin. For patients with ABL1 mutations and those who have relapsed or are refractory to other treatments, targeted oral small molecule drugs, monoclonal antibodies, Bispecific T cell Engagers (BiTE), and chimeric antigen receptor (CAR) T cells immunotherapy are emerging as potential treatment options. These new therapeutic interventions are changing the treatment landscape for PH + ALL. In summary, this review discusses the current advancements in targeted therapeutic agents shift in the treatment strategy of PH + ALL towards using more tolerable chemotherapy-free induction and consolidation regimens confers better disease outcomes and might obviate the need for HSCT.

01 Dec 2024·Endoscopy

Use of biliopancreatic duct imaging system in a 13-month-old girl to enable endoscopic removal of a foreign body in the appendix

Article

Author: Lou, Jingan ; Peng, Kerong ; Zhao, Hong ; Tang, Lujing

01 Nov 2024·Ophthalmology

Repeated Low-Level Red Light Therapy for Myopia Control in High Myopia Children and Adolescents

Article

Author: Li, Qian ; Zhu, Huang ; Zhang, Jian ; Kong, Miao ; Cui, Lipu ; Feng, Xueliang ; Cui, Hongping ; Shi, Caiping ; Zou, Haidong ; Xu, Yan ; Feng, Kehong

PURPOSETo assess the effectiveness and safety of repeated low-level red light (RLRL), which is a newly available treatment for myopia control in children and adolescents with high myopia.DESIGNMulticenter, randomized, parallel-group, single-blind clinical trial (randomized controlled trial; NCT05184621).PARTICIPANTSBetween February 2021 and April 2022, 192 children aged 6 to 16 years were enrolled. Each child had at least 1 eye with myopia of cycloplegic spherical equivalent refraction (SER) at least -4.0 diopters (D), astigmatism of ≤2.0 D, anisometropia of ≤3.0 D, and best-corrected visual acuity (BCVA) of 0.2 logarithm of the minimum angle of resolution or better. Follow-up was completed by April 2023.METHODSParticipants were randomly assigned at a 1:1 ratio to intervention (RLRL treatment plus single-vision spectacles) or control (single-vision spectacles) groups. The RLRL treatment was administered for 3 minutes per session, twice daily with a minimum interval of 4 hours, 7 days per week.MEAN OUTCOME MEASURESThe primary outcome and key secondary outcome were changes in axial length (AL) and cycloplegic SER measured at baseline and the 12-month follow-up visit. Participants who had at least 1 postrandomization follow-up visit were analyzed for treatment efficacy.RESULTSAmong 192 randomized participants, 188 (97.91%) were included in the analyses (96 in the RLRL group and 92 in the control group). After 12 months, the adjusted mean change in AL was -0.06 mm (95% confidence interval [CI], -0.10 to -0.02 mm) and 0.34 mm (95% CI, 0.30 to 0.39 mm) in the intervention and control groups, respectively. A total of 48 participants (53.3%) in the intervention group were still experiencing axial shortening >0.05 mm at the 12-month follow-up. The mean SER change after 12 months was 0.11 D (95% CI, 0.02to 0.19 D) and -0.75 D (95% CI, -0.88 to -0.62 D) in the intervention and control groups, respectively.CONCLUSIONSRepeated low-level red light demonstrates stronger treatment efficacy among those with high myopia, with 53.3% experiencing substantial axial shortening. Repeated low-level red light provides an excellent solution for the management of high myopia progression, a significant challenge in ophthalmology practice.FINANCIAL DISCLOSURE(S)The author(s) have no proprietary or commercial interest in any materials discussed in this article.

100 Deals associated with The Children's Hospital of Zhejiang University School of Medicine

Login to view more data

100 Translational Medicine associated with The Children's Hospital of Zhejiang University School of Medicine

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Anti-BCMA/CD70 CAR-T cells(The Children's Hospital of Zhejiang University School of Medicine) ( BCMA x CD70 )	Nephrotic Syndrome More	Phase 1
CN117965451 ( factor IX )	Blood Coagulation Disorders More	Discovery